# Roche Unveils Promising New Weight Loss Drug CT-388 in Early Trial Results



Swiss pharmaceutical company Roche has unveiled a new weight loss drug, CT-388, which has shown promising early trial results. In a phase 1 trial involving 31 obese adults without underlying conditions like type 2 diabetes, the once-weekly injection led participants to lose an average of 18.8% of their body weight over 24 weeks. Comparatively, semaglutide-based medications such as Ozempic and Wegovy typically result in approximately 10% weight loss over six months.

Roche's CT-388 functions by suppressing appetite through two hormones, Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP), making it similar to other weight loss drugs like Mounjaro and Zepbound, produced by Eli Lilly. Notably, 45% of the trial participants lost more than 20% of their body weight, and those with pre-diabetes entered remission by the end of the trial.

Despite the promising results, CT-388 has several phases of clinical trials remaining before it can seek approval. The drug's cost has not yet been disclosed. The announcement led to a four percent increase in Roche's share price. This development occurs amid a surge in the weight loss drug market, projected to reach $44 billion by 2030.